MSLN-targeting bispecific t-cell engaging antibody, MG1122, for treatment of solid tumors.
2018
e14500Background: Engaging T cells to attack tumors is a new class of immunotherapy. Tumor-specific T cell-engaging antibodies have an ability to redirect and activate T cells to target tumor cells...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI